Eurobio Scientific Announces First Real-World Results from RESCUE Trial Confirming EndoPredict’s Impact in Early Luminal Breast Cancer

 

Eurobio Scientific is proud to announce the first results from the RESCUE trial, the largest prospective, international, multicenter real-world study evaluating EndoPredict® in early luminal breast cancer. Performed by NOGGO e.V., the study recruited a total of 1,191 patients (49 drop-outs) across 45 sites in Germany and Switzerland, providing unprecedented insights into how genomic testing influences treatment decisions in routine clinical practice.¹

About the RESCUE Trial

 

RESCUE (Reaching for Evidence-based Chemotherapy Use in Endocrine Sensitive Breast Cancer) was designed to assess the impact of EndoPredict – a second-generation clinico-molecular test – on adjuvant therapy recommendations and patient compliance. Patients were eligible if they were pre- or postmenopausal and had a confirmed diagnosis of HR+/HER2– primary invasive breast cancer (Stage I/II; T1–T3) with 0–3 positive lymph nodes, and if an EndoPredict test had been performed within six months prior to enrollment. EndoPredict integrates a 12-gene molecular score with tumor size and nodal status to deliver a comprehensive risk assessment.²

 

Key Findings Presented at ESMO

 

The results, presented by PD Dr. Johannes Ettl (Kempten Hospital Group, Germany) during the ESMO Congress, highlight several important results:

• Clear Risk Stratification: EndoPredict reclassified a significant proportion of patients compared to clinical factors alone (almost 50% of G1 as EPclin high and 24% of G3 as EPclin low), providing actionable high- and low-risk categories.
• Clinico-Molecular Integration Adds Value: In 23% of cases, nodal status and tumor size influenced the final EPclin Class, demonstrating the importance of combining molecular and clinical data.
• High Clinical Confidence: Physicians largely followed EndoPredict results when making adjuvant chemotherapy decisions – even when Ki-67 suggested a different approach.
• Excellent Endocrine Therapy Adherence: Over 96% of patients remained compliant with endocrine therapy during the first year, reflecting strong trust in genomically guided treatment strategies.

 

Why This Matters

 

These findings confirm EndoPredict’s role as a clinically validated, guideline-endorsed tool that helps refine treatment choices, reduce unnecessary chemotherapy, and support personalized care for patients with ER-positive, HER2-negative early-stage breast cancer.

 

Next Steps

 

The RESCUE trial is ongoing, and three-year outcome data are expected next year. These results will provide even deeper insights into long-term patient outcomes and the real-world impact of genomic testing on survival and recurrence.

 

References:

Ettl J. et al.: EndoPredict in Patients with ER-positive, HER2-negative Early-Stage Breast Cancer: Data from the Prospective, International, Multicenter RESCUE Trial, 361P ESMO

Filipits M. et al.: A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors. Clin. Cancer Res. 2011